Page 3 - Preclinical Development News Today

Harvard researchers receive $1.2 million from CARB-X to develop enhanced oral antibiotics for drug-resistant bacteria listed by CDC.

EngineeringChapter1:VariousstagesofinnovativedrugresearchanddevelopmentTheresearchanddevelopmentofinnovativedrugsisa...

MONTPELLIER, France--(BUSINESS WIRE)--Jan 29, 2024--

Dublin, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The

QPS Holdings LLC QPS a global contract research organization CRO that provides discovery preclinical bioanalysis clinical trials and clinical research services is reinforcing its focus on qualitative and quantitative bioanalysis of biotherapeutics in Europe.

NEWARK, Del.--(BUSINESS WIRE)--#HRMS--QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is reinforcing its focus on qualitative and quantitative bioanalysis of biotherapeutics in Europe. QPS annou...

Oxford-based SynaptixBio, whose aim is to find a treatment for TUBB4A-related leukodystrophies, has been awarded a £490,000 BioMedical Catalyst grant from Innovate UK to tackle less common variants of the disease. TUBB4A-related leukodystrophies are a group of rare neurodegenerative diseases primarily affecting ...

Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The

Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode.

Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript November 7, 2023 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.11 EPS, expectations were $-0.09. Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. As […]